Steven Stice
Co-Founder & Chief Scientific Officer ArunA Bio
Seminars
Wednesday 24th September 2025
Update on Cleared US FDA IND for Acute Ischemic Stroke Using Neural Stem Cell Derived EVs
11:00 am
- AB126: A first-in-class EV Therapy for stroke and CNS diseases and designed to treat stroke patients with poor prognosis post-reperfusion: A high medical-need
- IND-cleared, with preliminary work underway for the first-in-human trial
- AB126 offers a novel, multi-target solution with a clear mechanisms or action that address inflammation, immune response and repair
NEW DATA!
Wednesday 24th September 2025
Biopharma Leaders Panel Discussion: Unlocking the Next Wave of Safe & Efficient Exosome-Based Therapeutics Towards Clinical & Commercial Reality
2:10 pm
This is your chance to hear from pioneering executive leaders from the exosome and extra-cellular vesicle community who will discuss their strategies, challenges, and future perspectives for exosome technology and clinically relevant therapeutic applications.
- What are the future opportunities, promising targets, and applications on the horizon for exosomes to achieve clinical success?
- What can we learn from past experiences, principles, and guidelines to roadmap and accelerate the next 5 years of therapeutic development?
- What advice can you give this room of exosome experts to reduce risk, extend cash flow, and become an investable SME?
Moderator: Michael Binks, Chief Medical Officer of Capricor Therapeutics
